Recent News

Cardiopulmonary Events: Study Finds Small but Real Risk After Partial Nephrectomy

ESMO 2021: Update From KEYNOTE-427 With Pembrolizumab Monotherapy for Kidney Cancer

Trends in Renal Cell Carcinoma in Pennsylvania Over the Past 27 Years

ESMO 2021: Patient-Reported Outcomes From KEYNOTE-564 With Adjuvant Pembrolizumab for Kidney Cancer

ESMO 2021: Can Modified Dosing Schedule of Ipilimumab Improve Tolerability in Renal Cell Carcinoma?

ESMO 2021: Temporary Treatment Cessation Versus Continuation in Advanced Kidney Cancer

ESMO 2021: 5-Year Outcomes With Nivolumab Plus Ipilimumab in Kidney Cancer

AUA 2021: Immunotherapy and Cytoreductive Nephrectomy in Metastatic Kidney Cancer

AUA 2021: Role of the Tumor Microenvironment and Response to Axitinib in Renal Cell Carcinoma

AUA 2021: KEYNOTE-564 Focuses on Adjuvant Immunotherapy for Renal Cell Carcinoma

Immune Checkpoint Inhibition in Metastatic Kidney Cancer: Racial Differences in Outcomes?

Reversible Aminotransferase Elevation in Patients Treated With Pembrolizumab/Axitinib for Kidney Cancer

Myasthenia Gravis: A Paraneoplastic Syndrome Linked to Renal Cell Carcinoma?

Renal Cell Carcinoma: Neoadjuvant Radiation Followed by Nephrectomy and Thrombectomy

Belzutifan Approved by FDA for von Hippel-Lindau Disease Associated With Kidney Cancer

Lenvatinib Plus Pembrolizumab Approved by FDA for Advanced Renal Cell Carcinoma

FDA Grants Priority Review to Pembrolizumab as Adjuvant Therapy After Nephrectomy

JAVELIN Renal 101 Trial: Second-Line Treatment With Axitinib Plus Avelumab in Kidney Cancer

MET-Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study

CheckMate 920: Nivolumab Plus Ipilimumab for Renal Cell Carcinoma With Brain Metastases

Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?

Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results

Nivolumab Alone and in Combination Therapy for Non–Clear Cell Kidney Cancer

Lenvatinib/Everolimus in Advanced Kidney Cancer: Outcomes in a Real-World Setting

Do Patient Demographics Influence Treatment Decisions in Kidney Cancer?

New Use for Older Antifungal Agent: Adjunct to Therapy for Kidney Cancer?

ASCO 2021: Telaglenastat Plus Cabozantinib in Advanced Renal Cell Carcinoma

ASCO 2021: mTOR- and VEGF-Targeted Agents in Metastatic Renal Cell Carcinoma

ASCO 2021: Does Immunotherapy Improve Outcomes in Aggressive Subtype of Kidney Cancer?

ASCO 2021: Impact of Lenvatinib-Based Therapy on Quality of Life in Renal Cell Carcinoma

ASCO 2021: Can Live Bacterial Product Enhance Response to Immunotherapy in Metastatic Renal Cell Cancer?

Updated AUA Guidelines Focus on Renal Masses and Localized Renal Cancer

ASCO 2021: 42-Month Follow-up of Pembrolizumab Plus Axitinib in Advanced Clear Cell Kidney Cancer

ASCO 2021: KEYNOTE-564 Evaluates Pembrolizumab as Adjuvant Therapy After Nephrectomy

After Radical Nephrectomy: Risk Factors Associated With Locoregional Recurrence

Advanced Kidney Cancer in Arizona: Are Hispanic and Native Americans at Increased Risk of Mortality?

Brain Metastasis 15 Years After Radical Nephrectomy for Renal Cell Carcinoma: Case Report

CRP Flare Response and Response to Nivolumab in Kidney Cancer

Stereotactic Body Radiotherapy for Metastatic Kidney Cancer: U.S. Temporal Trends

FDA Grants Priority Review to Pembrolizumab/Lenvatinib Combination for Kidney Cancer

Chemerin Overexpression in Clear Cell Kidney Cancer: Lipid Metabolism and Tumorigenesis

Is Plasma KIM-1 Linked to Recurrence Risk After Nephrectomy?

CheckMate 9ER: Cabozantinib Plus Nivolumab Versus Sunitinib in Kidney Cancer

Asymptomatic CNS Involvement From Advanced Renal Cell Carcinoma